Scarica l'app Stockscreener
53.31
5.71%
2.88
Dopo l'orario di chiusura:
53.00
-0.31
-0.58%
Precedente Chiudi:
$50.43
Aprire:
$49.03
Volume 24 ore:
1.64M
Relative Volume:
2.92
Capitalizzazione di mercato:
$2.64B
Reddito:
-
Utile/perdita netta:
$-105.43M
Rapporto P/E:
-23.00
EPS:
-2.3183
Flusso di cassa netto:
$-88.42M
1 W Prestazione:
+17.27%
1M Prestazione:
+58.24%
6M Prestazione:
+177.95%
1 anno Prestazione:
+465.92%
Intervallo 1D:
$49.00
$53.56
Intervallo di 1 settimana:
$43.50
$53.56
Portata 52W:
$5.485
$53.56
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Nome
Oruka Therapeutics Inc
Settore
Industria
Telefono
650-606-7910
Indirizzo
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
53.31 | 2.64B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Piper Sandler | Overweight |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-10-11 | Iniziato | Stifel | Buy |
| 2024-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | Leerink Partners | Outperform |
| 2024-09-16 | Iniziato | TD Cowen | Buy |
| 2024-09-13 | Iniziato | Jefferies | Buy |
| 2018-02-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Iniziato | Dawson James | Buy |
Mostra tutto
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
Does Oruka Therapeutics' (ORKA) $1 Billion Shelf Plan Reframe Its Long-Term Capital Strategy? - simplywall.st
ORKA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oruka Therapeutics may offer up to $1 billion of securities from time to timeSEC filing - MarketScreener
Oruka Therapeutics May Offer Up To $1 Billion Of Securities From Time To TimeSEC Filing - TradingView
Oruka Therapeutics (NASDAQ: ORKA) files $1B shelf to sell equity, warrants - Stock Titan
Oruka Therapeutics stock hits 52-week high at 50.11 USD By Investing.com - au.investing.com
HC Wainwright & Co. Maintains Oruka Therapeutics (ORKA) Buy Recommendation - MSN
ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors - TipRanks
Oruka Therapeutics stock hits 52-week high at 50.11 USD - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 18.4% in March - MarketBeat
How does Oruka Therapeutics Inc compare to its peersProfit Target & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Oruka Therapeutics and Clearmind Medicine Vie for Investor Dollars - National Today
Vanguard realignment leaves Oruka Therapeutics (ORKA) holdings at 0 after disaggregation - Stock Titan
458,946 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Synergy Asset Management LLC - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5.6%Here's Why - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD By Investing.com - Investing.com Australia
Momentum Shift: Will Oruka Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD - Investing.com
Aug Selloffs: Will Oruka Therapeutics Inc outperform tech stocksQuarterly Investment Review & AI Powered Market Entry Strategies - baoquankhu1.vn
Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)? - Yahoo Finance
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight - Investing.com
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US6876041087 - marketscreener.com
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | HQ1 | US6876041087 - marketscreener.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighStill a Buy? - MarketBeat
Does Oruka Therapeutics, Inc. (ORKA) have the potential to rally 41.51% as Wall Street analysts expect? - MSN
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock - Investing.com India
BTIG Reiterates Oruka Therapeutics (ORKA) Buy Recommendation - msn.com
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $16,313.50 in Stock - MarketBeat
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,641 Shares of Stock - MarketBeat
Oruka Therapeutics (ORKA) chief medical officer sells $313k in stock By Investing.com - za.investing.com
Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $71,407.70 in Stock - MarketBeat
Agarwal Arjun, Oruka Therapeutics SVP, sells $16k in ORKA stock - Investing.com Canada
[Form 4] Oruka Therapeutics, Inc. Insider Trading Activity - Stock Titan
Does Oruka Therapeutics, Inc. (ORKA) Have a Chance to Surge 41.51% According to Wall Street Analysts’ Predictions? - Bitget
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners - Defense World
Is Oruka Therapeutics’ (ORKA) ESOP Shelf Registration Quietly Redefining Its Funding Playbook? - simplywall.st
Oruka Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oruka Therapeutics, Inc. $ORKA is Fairmount Funds Management LLC's 7th Largest Position - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at Wall Street Zen - MarketBeat
Commodore Capital LP Has $33.71 Million Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Braidwell LP Sells 142,492 Shares of Oruka Therapeutics, Inc. $ORKA - MarketBeat
BTIG Research Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH) - The Globe and Mail
Oruka Therapeutics Inc Azioni (ORKA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):